منتديات ون توك تيكوم
أهلا وسهلا بكم في منتديات ون توك تيكوم نورتو المنتدى

تشرفنا بزيارتك النا ونتمنى تشارك ويانة

إدارة المنتدى
منتديات ون توك تيكوم
أهلا وسهلا بكم في منتديات ون توك تيكوم نورتو المنتدى

تشرفنا بزيارتك النا ونتمنى تشارك ويانة

إدارة المنتدى
منتديات ون توك تيكوم
هل تريد التفاعل مع هذه المساهمة؟ كل ما عليك هو إنشاء حساب جديد ببضع خطوات أو تسجيل الدخول للمتابعة.
منتديات ون توك تيكوم



 
الرئيسيةالرئيسية  أحدث الصورأحدث الصور  التسجيلالتسجيل  دخولدخول  
هلا بيك عيني نورتنا يلغالي ,,,نطمح بمشاركتك ويانة
دومن المنتدى هو WWW.TUCOMNA.ED وهو قيد التفعيل
مشاركتك ودعوتك لأصدقائك تعني لنا الكثير

 

 ...Abciximab

اذهب الى الأسفل 
كاتب الموضوعرسالة
Dr. X
مشرف عام
مشرف عام
Dr. X


ذكر
عدد الرسائل : 287
العمر : 36
المحافظة : فلسطيني
الهوايات : الفروسية,الرماية والسباحة
نقاط : 5864
التقييم : 0
تاريخ التسجيل : 19/10/2008

...Abciximab Empty
مُساهمةموضوع: ...Abciximab   ...Abciximab Icon_minitimeالأربعاء أكتوبر 29, 2008 4:31 pm

Abciximab (previously known as c7E3 Fab), manufactured by Centocor and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. Its mechanism of action is inhibition of glycoprotein IIb/IIIa.[citation needed]

While Abciximab has a short plasma half life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 24 to 48 hours after discontinuation of the drug.[citation needed]

Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane
Indications for use
Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure[1] and a decreased need for repeated coronary artery revascularization in the first month following the procedure.[2] Research also shows that this drug can be use for patients with diabetes and chronic renal insufficiency. Though it is not appropriate drug of choice if a patient is scheduled for an emergency surgery (ie:heart surgery) because bleeding time may take about 12hours to normalize.

Pharmacokinetics
Abciximab has a plasma half life of about ten minutes, with a second phase half life of about 30 minutes. However, its effects on platelet function can be seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated.

Side effects
Many of the side effects of abciximab are due to its anti-platelet effects. This includes an increased risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal hemorrhage.

Thrombocytopenia is a rare but known serious risk. Abciximab-induced thrombocytopenia can typically be treated with transfusion of platelets. Abciximab induced thrombocytopenia can last for five days after initial drug administration. Transfusing platelets is the only known treatment and may have limited effectiveness as the drug may also bind to the new platelets. Platelet counts which should average 250,000-400,000 can effectively drop to zero
الرجوع الى أعلى الصفحة اذهب الى الأسفل
 
...Abciximab
الرجوع الى أعلى الصفحة 
صفحة 1 من اصل 1

صلاحيات هذا المنتدى:لاتستطيع الرد على المواضيع في هذا المنتدى
منتديات ون توك تيكوم :: قسم طلاب تيكوم :: قسم الـpaharmacology :: haematology-
انتقل الى: